We feel it’s important to maintain a high level of thought leadership in our field, providing insight and guidance to the health science domain in order to better serve the interests of our customers and, ultimately, patients.
International health emergencies expose health data infrastructure gaps. 10 COVID-19 driver projects reveal data challenges and lessons for future preparedness.
DOI: 10.1016/S2589-7500(24)00028-1
How RWD and RWE advance clinical pharmacology and translational research — guidance on data access, quality assessment, and governance for RWD programmes.
DOI: 10.1111/cts.13785
AI for generating MIDD assets across the drug development continuum. Model-informed drug development, PK/PD modelling, and AI-assisted regulatory submissions.
DOI: 10.1208/s12248-023-00838-x
Question-centric regulatory decision-making in drug assessment. Aligning evidence generation, submission strategy, and regulatory dialogue in drug development.
DOI: 10.1002/cpt.2856
Systems biology and QSP for drug development in pregnancy. Addressing pharmacokinetic, pharmacodynamic, and safety knowledge gaps in maternal medicine.
DOI: 10.1002/jcph.2265
The Aridhia DRE enables AI across early-stage drug development: target identification, virtual screening, PKPD modelling, and candidate selection, securely.
DOI: 10.3389/fphar.2023.1115356
How RDCA-DAP is transforming rare disease drug development: Collaborative analytics, FAIR data, and secure research infrastructure powered by the Aridhia DRE.
DOI: 10.1007/s10928-023-09859-7
harmacometric modeller training - a multisector perspective on the skills, tools, and frameworks shaping the next generation of pharmacometricians.
DOI: 10.1007/s10928-023-09878-4
